Clinical Trial Update: A 5-Week Trial Of PD 0332334 And Alprazolam Extended Release Compared To Placebo In Patients With Generalized Anxiety Disorder [Phase 2]

View source ↗

Summary

A completed Phase 2 randomized trial evaluated PD 0332334 in combination with extended-release alprazolam versus placebo in Generalized Anxiety Disorder over fi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Generalized Anxiety Disorder

Drugs mentioned

• ALPRAZOLAM EXTENDED RELEASE (alprazolam)
• PD 0332334

Snippet

Sponsor: Pfizer | Conditions: Generalized Anxiety Disorder | Phase 2 | Status: COMPLETED